Overview

Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases

Status:
Not yet recruiting

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

Prospective, multicenter, comparative, randomized placebo-controlled Phase III trial - patients with hormone-naïve prostate cancer and pelvic lymph nodes metastases

Phase:

Phase 3

Details

Lead Sponsor:

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Collaborator:

Bayer